Did you know that there are now several biomarkers that can be used to guide immunotherapy choice for esophagogastric cancers? Join Drs. Shah and Uboha in a discussion on the latest in the field for immunotherapy treatment in esophogogastric cancer.
This activity is intended for oncologists, gastroenterologists, and pathologists on the esophagogastric cancer care team.
The goal of this activity is to enable clinicians in integrating immune checkpoint inhibitor (ICI)-based regimens for esophagogastric cancer in different treatment settings, including first-line and later for metastatic disease and adjuvant treatment.
Learning Objectives:
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Clinical evidence on the use of ICIs in esophagogastric cancers
- Role of biomarkers in treatment planning for ICI therapy in esophagogastric cancers
- Have greater competence related to
- Incorporating ICI therapy as treatment for esophagogastric cancer
- Demonstrate greater confidence in their ability to
- Individualizing ICI therapy as treatment for esophagogastric cancer
Approximate Time to Complete: 15 minutes
Credit Available: March 24, 2022 - March 24, 2023
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
- Have increased knowledge regarding clinical evidence on the use of ICIs in esophagogastric cancers.
- Have increased knowledge regarding the role of biomarkers in treatment planning for ICI therapy in esophagogastric cancers.
- Demonstrate greater confidence in the ability to individualize ICI therapy as treatment for esophagogastric cancer.
- Have increased knowledge regarding incorporating ICI therapy as treatment for esophagogastric cancer.